- Home
- MGNX vs FACWW Comparison
MGNX vs FACWW Comparison
Compare MGNX & FACWW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MGNX | FACWW |
|---|---|---|
| Founded | 2000 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Miscellaneous |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 220.6M | 231.2M |
| IPO Year | 2013 | 2025 |
Fundamental Metrics
Financial Performance| Metric | MGNX | FACWW |
|---|---|---|
| Price | $4.59 | $1.69 |
| Analyst Decision | Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $5.00 | N/A |
| AVG Volume (30 Days) | ★ 662.0K | 100.1K |
| Earning Date | 05-08-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $149,500,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.19 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.19 | $1.80 |
| 52 Week High | $4.64 | $2.25 |
Technical Indicators
Market Signals| Indicator | MGNX | FACWW |
|---|---|---|
| Relative Strength Index (RSI) | 65.09 | N/A |
| Support Level | $1.49 | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.29 | 0.00 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 69.03 | 0.00 |
Price Performance
Historical ComparisonAbout MGNX MacroGenics Inc.
Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.